Abstract
Introduction
Lysis syndrome is a constellation of metabolic disorders usually seen after the initiation of chemotherapy for rapidly proliferating malignancies (tumor lysis syndrome). Reported herein is a tumor lysis-like syndrome after the initiation of anti-infective therapy for visceral leishmaniasis.
Patients and methods
Ten consecutive patients with visceral leishmaniasis were administered liposomal amphotericin B. Levels of serum uric acid, phosphate, creatinine, blood urea nitrogen, potassium, calcium, and magnesium were evaluated prior to as well as 4 and 30 days following the initiation of treatment.
Results
During the 4th post-treatment day significant increases in the levels of serum uric acid, phosphate, creatinine, and blood urea nitrogen were seen, while the levels of calcium, potassium, and magnesium were not significantly altered. Patients were treated by hydration, urine alkalization, and administration of allopurinol as needed. A recovery of metabolic abnormalities was recorded 1 month later, although some patients had evidence of residual injury.
Conclusion
A lysis syndrome may complicate the treatment of visceral leishmaniasis. Awareness of this complication can lead to the initiation of prophylactic treatment as well as to early recognition and management of this syndrome in susceptible patients.
Similar content being viewed by others
References
Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol. 1993;13:273–80.
Jeha S. Tumor lysis syndrome. Semin Hematol. 2001;38:4–8.
Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206–12.
Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis. 2010;14:e1032–9.
Daher EF, Evangelista LF, Silva Junior GB, et al. Clinical presentation and renal evaluation of human visceral leishmaniasis (kala-azar): a retrospective study of 57 patients in Brazil. Braz J Infect Dis. 2008;12:329–32.
Delgado J, Macias J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg. 1999;61:766–9.
Liberopoulos E, Alexandridis G, Elisaf M. A tumor lysis-like syndrome during therapy of visceral leishmaniasis. Ann Clin Lab Sci. 2002;32:419–21.
MDRD GFR calculator. Available from: http://www.nephron.com/MDRD_GFR.cgi Last assessed 3 Sep, 2011.
Hurley JC. Antibiotic-induced release of endotoxin: a reappraisal. Clin Infect Dis. 1992;15:840–54.
Hsu HH, Chan YL, Huang CC. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol. 2004;17:50–6.
Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546–54.
Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010;89:236–44.
Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362:504–12.
Conflict of interest
None relevant to this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liberopoulos, E.N., Kei, A.A. & Elisaf, M.S. Lysis syndrome during therapy of visceral leishmaniasis. Infection 40, 121–123 (2012). https://doi.org/10.1007/s15010-011-0202-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-011-0202-9